NEW YORK, March 19, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), WellCare Health Plans, Inc. (NYSE: WCG), Zogenix, Inc. (NASDAQ: ZGNX), Orexigen Therapeutics, Inc. (NASDAQ: OREX), and XOMA Corporation (NASDAQ: XOMA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Keryx Biopharmaceuticals Inc. Analyst Notes
On March 12, 2014, Keryx Biopharmaceuticals Inc. (Keryx) reported its Q4 2013 and full-year 2013 financial results. Net loss for Q4 2013 was $17.7 million or $0.21 per diluted share, compared to net loss of $6.6 million or $0.09 per diluted share in Q4 2012. Full-year 2013 net loss was $46.7 million or $0.58 per diluted share, compared to net loss of $22.7 million or $0.32 per diluted share in full-year 2012. According to the Company, as on December 31, 2013, the Keryx had cash and cash equivalents of $55.7 million, as compared to $14.7 million as recorded on December 31, 2012. The full analyst notes on Keryx Biopharmaceuticals Inc. are available to download free of charge at:
WellCare Health Plans, Inc. Analyst Notes
On March 10, 2014, WellCare Health Plans, Inc. (WellCare) announced that it is working with MyHealthDirect to make scheduling doctors' appointments easier and more convenient for its members and health care providers in Georgia. According to the Company, WellCare Medicaid, and Medicare Advantage members who are patients of providers that participate in the program will be able to work directly with WellCare representatives for appointment scheduling, immediate appointment confirmation and to receive text and email appointment reminders. Roman Kulich, WellCare's Region President for Georgia and South Carolina, stated, "WellCare is working to improve our members' access to care by providing solutions that streamline the process. This tool is another way that we are making it easier for our members to get the quality care they need, while offering increased convenience and administrative savings for providers, and reducing overall costs." The full analyst notes on WellCare Health Plans, Inc. are available to download free of charge at:
Zogenix, Inc. Analyst Notes
On March 7, 2014, Zogenix, Inc. (Zogenix) announced that the American Academy of Pain Medicine (AAPM) has presented Marsha R. Stanton, Ph.D., RN, Executive Director of Medical Affairs at Zogenix, with the Distinguished Service Award. According to the Company, the recognition is given annually to honor an individual for their outstanding commitment and contributions to the field of pain medicine and the AAPM. Bradley S. Galer, M.D., Executive Vice President and Chief Medical Officer of Zogenix, stated, "We congratulate Dr. Stanton on receiving this prestigious award and are proud to have her as part of our Medical Affairs team. She offers a wealth of experience and insight into pain medicine and we look forward to her leadership and guidance as we continue to deliver on our mission of developing and commercializing therapies that address specific clinical needs for people living with pain-related conditions." The full analyst notes on Zogenix, Inc. are available to download free of charge at:
Orexigen Therapeutics, Inc. Analyst Notes
On March 12, 2014, Orexigen Therapeutics, Inc. (Orexigen Therapeutics) announced its Q4 2013 and full-year 2013 financial results. Total revenues remained flat at $0.9 million and $3.4 million for Q4 2013 and full-year 2013, respectively. Net loss for Q4 2013 was $21.5 million or $0.21 per diluted share, compared to net loss of $32.5 million or $0.41 per diluted share in Q4 2012. Net loss for full year 2013 was $77.7 million or $0.80 per diluted share, compared to net loss of $90.1 million or $1.27 per diluted share in full year 2012. Michael Narachi, CEO of Orexigen Therapeutics, stated, "We expect 2014 will be a transformative year for Orexigen with the following key catalysts: a US approval, a well resourced US primary care launch by Takeda, a positive CHMP opinion, an EU approval, and progress toward a partnership to commercialize NB32 outside North America." The full analyst notes on Orexigen Therapeutics, Inc. are available to download free of charge at:
XOMA Corporation Analyst Notes
On March 4, 2014, XOMA Corporation (XOMA) reported its Q4 2013 and full-year 2013 financial results. Q4 2013 total revenues went up by 69.6% YoY to $12.5 million, while full-year 2013 total revenues went up by 4.9% YoY to $35.5 million. Net loss for Q4 2013 was $52.3 million or $0.55 per diluted share, compared to Q4 2012 net income of $2.4 million or $0.03 per diluted share. Full-year 2013 net loss was $124.1 million or $1.43 per diluted share, compared to full-year 2012 net loss of $71.1 million or $1.10 per diluted share. According to XOMA, it anticipates cash used in ongoing activities during 2014 to be c. $55.0 million to $60.0 million, primarily reflecting the costs associated with conducting the gevokizumab three Phase 3 clinical trials in the EYEGUARD program and the costs associated with conducting a Phase 3 clinical trial in patients with pyoderma gangrenosum. The full analyst notes on XOMA Corporation are available to download free of charge at:
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review